EFFECTS OF METHANOL LEAF EXTRACT OF MORINGA OLEIFERA ON NEUROBEHAVIOURAL AND OXIDATIVE STRESS CHANGES INDUCED BY SUBCHRONIC EXPOSURE TO CHLORPYRIFOS IN MALE WISTAR RATS
Table Of Contents
<p> <b>TABLE OF CONTENTS </b></p><p>Declaration....................................................................................................................... iii </p><p>Certification ..................................................................................................................... iv </p><p>Dedication......................................................................................................................... v </p><p>Acknowledgments ........................................................................................................... vi </p><p>Abstract........................................................................................................................... vii </p><p>Table of Contents............................................................................................................. ix </p><p>List of Tables................................................................................................................. xiv </p><p>List of Figures................................................................................................................. xv </p><p>List of Plates ................................................................................................................. xvii </p><p>List of Abbreviations................................................................................................... xviii </p><p>
Chapter ONE
: INTRODUCTION........................................................................... 1 </p><p>1.1 Background ......................................................................................................... 1 </p><p>1.2 Statement of Research Problem ........................................................................ 3 </p><p>1.3 Justification ......................................................................................................... 5 </p><p>1.4 General Aim of the Study................................................................................... 6 </p><p>1.5 Objectives of the Study....................................................................................... 6 </p><p>1.6 Research Hypothesis (H0)................................................................................... 7 </p><p>
Chapter TWO
: LITERATURE REVIEW.............................................................. 8 </p><p>2.1 Pesticides.............................................................................................................. 8 </p><p>2.1.1 Classification of pesticides ................................................................................... 8 </p><p>2.2 Organophosphates.............................................................................................. 9 </p><p>2.2.1 Classification of organophosphates...................................................................... 9 </p><p>2.2.2 History of organophosphates.............................................................................. 10 </p><p>2.2.3 Uses of organophosphates .................................................................................. 11 </p><p>2.2.4 Mechanism of action of organophosphates ........................................................ 12 </p><p>2.2.5 Organophosphate toxicity................................................................................... 13 </p><p>2.3 Chlorpyrifos ...................................................................................................... 19 </p><p>2.3.1 Pharmacodynamics of chlorpyrifos.................................................................... 20 </p><p>2.3.2 Pharmacokinetics of chlorpyrifos....................................................................... 20 </p><p>2.3.3 Chlorpyrifos toxicity........................................................................................... 22 </p><p>2.4 Formation and Action of Reactive Oxygen Species....................................... 29 </p><p>2.4.1 Effects of free radicals on biological systems .................................................... 31 </p><p>2.5 Antioxidants and their Defence System.......................................................... 33 </p><p>2.5.1 Antioxidants........................................................................................................ 33 </p><p>2.5.2 Antioxidant defence system................................................................................ 35 </p><p>2.6 Oxidative Stress - a Mechanism of Chlorpyrifos Toxicity ............................ 36 </p><p>2.7 Moringa oleifera ................................................................................................ 38 </p><p>2.7.1 Moringa oleifera: description ............................................................................. 38 </p><p>2.7.2 Nutritional properties and ethnomedical uses of Moringa oleifera.................... 39 </p><p>2.7.3 Antioxidant properties of Moringa oleifera........................................................ 40 </p><p>
Chapter THREE
: MATERIALS AND METHODS ............................................ 42 </p><p>3.1 Plant Materials.................................................................................................. 42 </p><p>3.1.1 Plant collection, identification, extraction and preparation ................................ 42 </p><p>3.1.2 Phytochemical screening of leaf extract ............................................................. 42 </p><p>3.1.3 Quantitative analysis of methanol extract of Moringa oleifera leaf for flavonoids
and antioxidant vitamins..................................................................................... 43 </p><p>3.2 Chemical Acquisition and Preparation .......................................................... 43 </p><p>3.3 LD50 Determination .......................................................................................... 43 </p><p>3.4 Experimental Animals...................................................................................... 44 </p><p>3.5 Experimental Groupings/Treatments............................................................. 44 </p><p>3.6 Evaluation of neurobehavioural and cognitive changes................................ 45 </p><p>3.6.1 Open-field assessment ........................................................................................ 45 </p><p>3.6.2 Assessment of neuromuscular coordination …………………………………….…...46 </p><p>3.6.3 Assessment of motor coordination ..................................................................... 46 </p><p>3.6.4 Assessment of locomotor efficiency................................................................... 47 </p><p>3.6.5 Assessment of motor strength............................................................................. 47 </p><p>3.6.6 Assessment of excitability score......................................................................... 47 </p><p>3.6.7 Assessment of depression ................................................................................... 48 </p><p>3.6.8 Evaluation of learning and short-term memory.................................................. 48 </p><p>3.7 Preparation of Brain Samples ......................................................................... 49 </p><p>3.8 Assessment of Acetylcholinesterase Activity .................................................. 49 </p><p>3.9 Assessment of Brain Lipoperoxidation........................................................... 50 </p><p>3.10 Assessment of Brain Antioxidant Enzyme Activities .................................... 50 </p><p>3.11 Histopathology .................................................................................................. 51 </p><p>3.12 Data Analysis..................................................................................................... 52 </p><p>
Chapter FOUR
: RESULTS.................................................................................... 53 </p><p>4.1 Determination of Median Lethal Dose............................................................ 53 </p><p>4.1.1 Determination of median lethal dose for chlorpyrifos........................................ 53 </p><p>4.1.2 Determination of median lethal dose for Moringa oleifera leaf extract............. 55 </p><p>4.2 Moringa oleifera Leaf: Methanol Extract Characteristics............................ 55 </p><p>4.2.1 Methanol extract yield of moringa oleifera leaf................................................. 55 </p><p>4.2.2 Phytochemical components of methanol extracts of Moringa oleifera leaf....... 55 </p><p>4.2.3 Flavonoid and antioxidant vitamin contents of Moringa oleifera leaf extract ... 57 </p><p>4.3 Subchronic Toxicity Study............................................................................... 59 </p><p>4.3.1 Clinical signs....................................................................................................... 59 </p><p>4.4 Effect of Treatments on Neurobehaviour....................................................... 59 </p><p>4.4.1 Effect of treatments on open-field performance ................................................. 59 </p><p>4.4.2 Effect of treatments on beam-walk score ........................................................... 75 </p><p>4.4.3 Effect of treatments on ladder-walk performance .............................................. 77 </p><p>4.4.4 Effect of treatments on inclined plane performance........................................... 80 </p><p>4.4.5 Effect of treatments on forepaw grip time .......................................................... 82 </p><p>4.4.6 Effect of treatments on excitability scores.......................................................... 85 </p><p>4.4.7 Effect of treatments on forced swimming test.................................................... 88 </p><p>4.4.8 Effect of treatments on learning acqusition ........................................................ 91 </p><p>4.4.9 Effect of treatments on short-term memory........................................................ 91 </p><p>4.5 Effect of Treatments on Brain Acetylcholinesterase Activity....................... 94 </p><p>4.6 Effect of Treatments on Brain Malondialdehyde Concentration................. 94 </p><p>4.7 Effect of Treatments on Brain Antioxidant Enzymes ................................... 97 </p><p>4.7.1 Effect of treatments on brain superoxide dismutase activity.............................. 97 </p><p>4.7.2 Effect of treatments on brain glutathione peroxidase activity ............................ 97 </p><p>4.7.3 Effect of treatments on brain catalase activity.................................................... 97 </p><p>4.8 Effect of Treatments on Brain Histo-architecture....................................... 102 </p><p>
Chapter FIVE
: DISCUSSION ............................................................................. 109 </p><p>CHAPTER SIX: CONCLUSION AND RECOMMENDATIONS ........................ 130 </p><p>6.1 Conclusion ....................................................................................................... 130 </p><p>6.2. Recommendations........................................................................................... 130 </p><p>6.2.1 Specific recommendations................................................................................ 130 </p><p>6.2.2 General recommendations ................................................................................ 131 </p><p>REFERENCES…………………………………………………………………………….……… 132
<br></p>
Thesis Abstract
<p> <b>ABSTRACT </b></p><p>The aim of the study was to investigate the modulatory role of methanol extract of
Moringa oleifera leaves (MO) on neurotoxicity induced by chlorpyrifos (CPF) exposure.
The methanol extract of the MO leaves were first subjected to qualitative phytochemical
screening. The quantity of flavonoids was evaluated using the High performance Liquid
Chromatography (HPLC) while vitamins A, C and E were also evaluated using
ultraviolet-visible spectroscopy. To investigate the modulatory role of MO leaves on
CPF-induced neurotoxicty, 60 male Wistar rats were divided into 6 groups of 10 animals
each.Group I was administered with distilled water (2 ml/kg); Group II, with soya oil (2
ml/kg); Group III, with MO (500 mg/kg); and Group IV, with CPF (9.8 mg/kg~1/10th of
the LD50 determined). Groups V and VI were administered with MO at 250 mg/kg and
500 mg/kg, respectively, 30 min before administration of CPF (9.8 mg/kg). The regimens
were administered once daily via gavage for a period of 9 weeks. Animals were subjected
to neurobehavioural tests such as open field (measuring frequency of locomotion, rearing,
stretch–attends posture, defaecation and urination), beam-walk (measuring motor
coordination), ladder walk, (measuring efficiency of locomotion) inclined plane
(measuring neuromuscular coordination), forepaw grip time (measuring motor strength),
excitability scores and forced swimming (measuring depression) on day 0, weeks 3, 6 and
9 of administration, and then step-down avoidance test (measuring learning and shortterm memory) at the end of extract administration. Thereafter, the animals were sacrificed
and the brain tissues harvested. The homogenates were assayed for levels of
acetylcholinesterase (AChE), superoxide dismutase (SOD), glutathione peroxidase
(GPX) and catalase (CAT) and malondialdehyde (MDA). Brain tissue was also processed
for histopathological examinations. The phytochemical screening indicated that MO
extract was positive for alkaloids, flavonoids, glycosides, phenol, saponin, tannin and
terpenoids. Quantitative analysis of the antioxidant components of the plant showed that
the flavonoid, vitamins A, C and E contents of the plant were 22.6% w/w, 0.3 mg/g, 6.7
mg/g and 0.22 IU/g, respectively. The result of the subchronic toxicity showed that CPF
decreased (P < 0.05) frequency of locomotion and rearing, indicating deficiency of motor
activity, and increased (P < 0.05) the frequency of stretch-attends posture and defaecation
in the open field, demonstrating anxiogenic response. The CPF induced significant (P <
0.05) deficits in beam-walk score, forepaw grip time, ladder work, forced swimming time
and excitability score, while it marginally increased (P > 0.05) the number of foot shocks,
but decreased significantly (P < 0.05) the time spent on the platform in the step-down
avoidance inhibition apparatus indicating apparent deficits in learning and significant
deficit in short-term memory, respectively. The CPF group also showed an increase in
brain MDA concentration and reduction in the activities of SOD, GPx but an increase in
the activity of CAT, indicating oxidative stress. Histopathology revealed that CPF
induced neuronal degeneration. Pretreatment with MO extract mitigated the deficit in
motor activity, anxiety, motor coordination, neuromuscular coordination, motor strength,
excitability scores, depression, learning and short-term memory provoked by subchronic
CPF administration. MO pretreatment modulated the brain AChE activity and mitigated
the neuronal degeneration provoked by CPF. MO also mitigated the CPF-induced
oxidative stress in the brain by reducing MDA concentration and modulated the activities
of SOD, CAT and GPx, demonstrating its antioxidant effect. In conclusion, MO
pretreatment mitigated CPF-evoked neurotoxicity due to the flavonoid, vitamins C and E
contents of the plant extract, which confers its antioxidant and AChE restorative
properties.
<br></p>
Thesis Overview